CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals

The role of genetic polymorphisms in cytochrome (CYP) 2D6 involved in the metabolism of 3,4-methylene-dioxymethamphetamine (MDMA, ecstasy) is unclear. Effects of genetic variants in CYP2D6 on the pharmacokinetics and pharmacodynamic effects of MDMA were characterized in 139 healthy individuals (70 m...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pharmacogenet Genomics
Main Authors: Schmid, Yasmin, Vizeli, Patrick, Hysek, Cédric M., Prestin, Katharina, Meyer zu Schwabedissen, Henriette E., Liechti, Matthias E.
Formato: Artigo
Idioma:Inglês
Publicado: Lippincott Williams & Wilkins 2016
Assuntos:
Short Communication
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4949007/
https://ncbi.nlm.nih.gov/pubmed/27253829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0000000000000231
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares